Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin e2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%

Retina

Volumn 29, Issue 9, 2009, Pages 1310-1313

  Heier, Jeffrey S ^a   Awh, Carl C ^b   Busbee, Brandon G ^b   Waterbury, L David ^c   Daniel, Paul ^a   Stoller, Glenn L ^d   Cleary, Tina S ^a  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b Retina Vitreous Associates   (United States)

^c Pacific BioLabs   (United States)

^d OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

Author keywords

Bromfenac; Inflammation; Ketorolac; Nepafenac; PGE2; Vitrectomy; Vitreous

Indexed keywords

BROMFENAC; KETOROLAC; KETOROLAC TROMETAMOL; NEPAFENAC; PROSTAGLANDIN E2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG PENETRATION; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; PREOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA MACULA HOLE; RETINA TEAR; VITRECTOMY; VITREOUS BODY;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENEACETAMIDES; BENZOPHENONES; BIOLOGICAL AVAILABILITY; BROMOBENZENES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DINOPROSTONE; FEMALE; HUMANS; KETOROLAC; MALE; MASS SPECTROMETRY; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PHENYLACETATES; RETINAL DISEASES; TISSUE DISTRIBUTION; VITRECTOMY; VITREOUS BODY;

EID: 70350161079     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181b094e6     Document Type: Article

References (12)

1. Colin J. The role of NSAIDs in the management of postoperative ophthalmic inflammation. Drugs 2007;67:1291-1308.
2. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol 1987;103:479-486.
3. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003;29:2378-2384.
4. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-519.
5. Heier JS, Topping TM, Baumann W, Dirks MS, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology 2000;107:2034-2038.
6. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol 2008;146:554-560.
7. Perry HD, Donnenfeld ED. An update on the use of ophthalmic ketorolac tromethamine 0.4%. Expert Opin Pharmacother 2006;7:99-107.
8. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000; 24:371-384.
9. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 2000; 24:357-370. (Pubitemid 30367882)
10. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27:281-291.
11. Bucci FA, Waterbury LD, Amico LM. Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0.4% (Acular LS) and nepafenac 0.1% (Nevanac) in patients undergoing phacoemulsification. Am J Ophthalmol 2007;144:146-147.
12. Bucci FA Jr, Waterbury LD. Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: aqueous drug absorption and prostaglandin E2 levels. J Cataract Refract Surg 2008;34:1509-1512.